vancomycin + metronidazole + ciprofloxacin

This drug is a **combination therapy** of three antibiotics: **vancomycin** (a glycopeptide antibiotic), **metronidazole** (a nitroimidazole antibiotic), and **ciprofloxacin** (a second-generation fluoroquinolone). It is not marketed under a unique brand name, but may be used in clinical contexts for **broad-spectrum antibacterial coverage**, particularly in severe or refractory infections where both aerobic and anaerobic pathogens may be present. Combination regimens with these three drugs have been studied for their profound effects on the **intestinal microbiota**, causing a significant short-term reduction in bacterial diversity and long-term alterations in the microbiome composition. Each component has a distinct mechanism: vancomycin inhibits bacterial cell wall synthesis (primarily Gram-positive bacteria); metronidazole disrupts DNA synthesis in anaerobic bacteria and certain protozoa; ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, primarily targeting Gram-negative and some Gram-positive bacteria[3][4][5][7]. This combination is sometimes used in research settings or for severe infections, but is not a standard commercial drug formulation.

Other names

Gut microbiota depletion regimenBroad-spectrum antibiotic cocktail